PharmaLegacy Laboratories, a leading provider of in vitro and in vivo preclinical drug development services, has acquired BTS Research, a San Diego-based preclinical contract research organization (CRO). This acquisition marks a significant milestone for PharmaLegacy as it strengthens its global research capabilities and service offerings. San Diego, recognized as a major global hub for research and development, offers PharmaLegacy a strategic foothold in the area and a deeper connection with the broader scientific community.
“PharmaLegacy has long served the U.S. markets, and establishing a local presence in San Diego’s biotechnology sector will accelerate our growth,” said Jeff Duan, founder and CEO of PharmaLegacy. “This acquisition enables us to better serve clients across the U.S. and North America, expanding our capacity for studies and enhancing flexibility for all our clients. It represents a pivotal move in our journey to becoming a leading preclinical CRO.”
The combination of PharmaLegacy and BTS Research will offer pharmaceutical, biotechnology, medical device, and diagnostics companies more comprehensive and reliable pharmacology data to advance treatments for patients. With decades of collective experience, this acquisition adds GLP toxicology services to PharmaLegacy’s already extensive range of pharmacology services.
“We are thrilled to join the PharmaLegacy family,” said Sami Abunadi, President of BTS Research. “By integrating our expertise, we will deliver top-tier research services to support the development of drugs, devices, and diagnostics. This partnership strengthens our position as a highly competitive global CRO.
About PharmaLegacy Laboratories:
PharmaLegacy is a CRO founded in 2008 which provides efficient and cost-effective preclinical in vitro and in vivo pharmacology studies to life science organizations. PharmaLegacy boasts a thousand of validated in vitro and in vivo services across over 40 different diseases, and has contributed to over 400 IND applications.
About BTS Research:
BTS Research is a San Diego-based Contract Research Organization that delivers GLP and Non-GLP biological services to clients in pharmaceutical, biopharmaceutical, biotech, academic research, medical device, and related industries, and has roots dating back to 2001 (formerly Bio-Quant, Inc. and BioTox Sciences). The Company was founded in 2007 and acquired Bio-Quant in 2011.
